(Q48017947)

7 February 2018

editorial

0 references

title

Current clinical trial design issues in hormone-refractory prostate carcinoma. Consensus Panel (English)

1 reference

7 February 2018

author name string

Vogelzang NJ

series ordinal

1

1 reference

7 February 2018

Crawford ED

series ordinal

2

1 reference

7 February 2018

Zietman A

series ordinal

3

1 reference

7 February 2018

language of work or name

English

0 references

publication date

1 June 1998

1 reference

7 February 2018

published in

Cancer

1 reference

7 February 2018

volume

82

1 reference

7 February 2018

issue

11

1 reference

7 February 2018

page(s)

2093-2101

1 reference

7 February 2018

cites work

Cancer statistics, 1991.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

21 January 2018

Cancer statistics, 1996.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

An adjustment to the 1997 estimate for new prostate cancer cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

Chemotherapy of advanced prostatic cancer. Evaluation of response parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123127), 5-fluorouracil (NSC 19893), and cyclophosphamide in the treatment of metastatic prostatic cancer. A randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

Phase III trial of cyclophosphamide versus cyclophosphamide, doxorubicin, and methotrexate in hormone-refractory prostatic cancer. A Hoosier Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

Report on the American Urologic Association/American Cancer Society scientific seminar on the detection and treatment of early-stage prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

Single-dose half-body irradiation for palliation of multiple bone metastases from solid tumors. Final Radiation Therapy Oncology Group report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

Bisantrene in advanced, hormone-resistant carcinoma of the prostate: an Illinois Cancer Council phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

Preclinical and clinical perspectives on the use of estramustine as an antimitotic drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

One hundred thirteen men with hormone-refractory prostate cancer died today

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

Chemotherapy of Advanced Prostatic Carcinoma with Cyclophosphamide or 5-Fluorouracil: Results of First National Randomized Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

Treatment plans for black and white women with stage II node-positive breast cancer. The National Cancer Institute Black/White Cancer Survival Study experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer--Genitourinary Group Study 30853

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

Importance of continued testicular suppression in hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

Bicalutamide for advanced prostate cancer: the natural versus treated history of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

Phase II trial of amonafide for the treatment of advanced, hormonally refractory carcinoma of the prostate. A Southwest Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

Phase II evaluation of ifosfamide/mesna in metastatic prostate cancer. A Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

Cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of metastatic prostate cancer. A Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

Doxorubicin, mitomycin C and 5-fluorouracil in the treatment of hormone refractory adenocarcinoma of the prostate: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

A phase ii trial of oral estramustine and oral etoposide in hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

Comparison of Estramustine Phosphate and Vincristine Alone or in Combination for Patients with Advanced, Hormone Refractory, Previously Irradiated Carcinoma of the Prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

Combination chemotherapy in advanced prostate cancer: a silk purse?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

THE USE OF PROSTATE-SPECIFIC ANTIGEN AS A SURROGATE END POINT IN THE TREATMENT OF PATIENTS WITH HORMONE REFRACTORY PROSTATE CANCER

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819980601%2982%3A11%3C2093%3A%3AAID-CNCR3%3E3.0.CO%3B2-X

10.1002/(SICI)1097-0142(19980601)82:11<2093::AID-CNCR3>3.0.CO;2-X

21 January 2018

Identifiers

DOI

1 reference

7 February 2018

1 reference

7 February 2018